scholarly journals Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice

HIV Medicine ◽  
2015 ◽  
Vol 17 (7) ◽  
pp. 495-504 ◽  
Author(s):  
E McKinnon ◽  
A Castley ◽  
L Payne ◽  
S Pummer ◽  
D Nolan
Keyword(s):  
Hiv Treatment ◽  
Treatment Choice ◽  
Hiv Rna ◽  
Residual Viraemia ◽  
Rna Levels

Gender Difference in HIV RNA Levels: A Meta-Analysis of Published Studies

2002 ◽  
Vol 31 (1) ◽  
pp. 11-19 ◽  
Author(s):  
Sonia Napravnik ◽  
Charles Poole ◽  
James C. Thomas ◽  
Joseph J. Eron
Keyword(s):  
Gender Difference ◽  
Meta Analysis ◽  
Hiv Rna ◽  
Rna Levels

Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug Resistance

2001 ◽  
Vol 28 (2) ◽  
pp. 105-113 ◽  
Author(s):  
James W. T. Cohen Stuart ◽  
Annemarie M. J. Wensing ◽  
Colin Kovacs ◽  
Maike Righart ◽  
Dorien de Jong ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Hiv Rna ◽  
Rna Levels

scholarly journals Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy

1998 ◽  
Vol 72 (6) ◽  
pp. 5154-5164 ◽  
Author(s):  
P. Scott Eastman ◽  
John Mittler ◽  
Reed Kelso ◽  
Chris Gee ◽  
Eric Boyer ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Resistance Mutation ◽  
Virologic Response ◽  
Hiv Rna ◽  
Immunodeficiency Virus ◽  
Plasma Rna ◽  
Doubling Times ◽  
Rna Levels

ABSTRACT Ten subjects received 600 to 1,200 mg of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor ritonavir per day. Following 2 weeks of therapy, plasma HIV RNA levels decreased by a mean of 1.57 (range, 0.89 to 1.96) log units. With continued therapy, HIV RNA levels began to rise in eight subjects. The initial rise in plasma RNA levels was temporally associated with the development and quantitative increase in the V82 resistance mutation. Doubling times of the V82A mutant virus were estimated to be 2.4 to 4.8 days. An L63P/A mutation was commonly present at baseline even in subjects with a durable virologic response. The concomitant acquisition of an L63P/A mutation with the V82A/F mutation at the time when plasma RNA levels rebounded suggests a role for the L63P/A mutation in improving the fitness of the V82A/F mutation. Subsequent additional genotypic changes at codons 54 and 84 were often associated with further increases in plasma RNA levels. Ongoing viral replication in the presence of drugs resulted in the appearance of additional genotypic changes, including the L90M saquinavir resistance mutation, and decreased phenotypic susceptibility. The relative fitness of the protease V82A ritonavir resistance mutation and reverse transcriptase T215Y/F zidovudine resistance mutation following drug withdrawal were estimated to be 96 to 98% that of the wild type. Durability of the virologic response was associated with plasma RNA levels at the nadir. A virologic response beyond 60 days was not observed unless plasma HIV RNA levels were suppressed below 2,000 copies/ml, consistent with estimates from V82A doubling times for selection of a single resistance mutation to dominate the replicating population.

scholarly journals Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL--authors' response

2012 ◽  
Vol 67 (10) ◽  
pp. 2541-2542
Author(s):  
N. Gianotti ◽  
L. Galli ◽  
S. Racca ◽  
S. Salpietro ◽  
F. Cossarini ◽  
...  
Keyword(s):  
Hiv Rna ◽  
Residual Viraemia

Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates

AIDS ◽  
2004 ◽  
Vol 18 (12) ◽  
pp. 1697-1705 ◽  
Author(s):  
Giota Touloumi ◽  
Nikos Pantazis ◽  
Abdel G Babiker ◽  
Sarah A Walker ◽  
Olga Katsarou ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Hiv Rna ◽  
Hiv 1 ◽  
Rna Levels

scholarly journals Accuracy of a Commercial Real‐Time Polymerase Chain Reaction–Based System for Measurement of HIV RNA Levels around the Limit of Quantification of the Assay

2009 ◽  
Vol 48 (11) ◽  
pp. 1630-1631 ◽  
Author(s):  
Alessandra Amendola ◽  
Maria Grazia Milia ◽  
Valeria Ghisetti ◽  
Carla Brega ◽  
Paola Zaccaro ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Real Time ◽  
Chain Reaction ◽  
Limit Of Quantification ◽  
Hiv Rna ◽  
Polymerase Chain ◽  
Rna Levels

scholarly journals A Prediction Model of Pretreatment HIV RNA Levels in Naïve Thai HIV-infected Patients: An Application for Resource-limited Settings

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S434-S434
Author(s):  
Nisha Pongpech ◽  
Anchalee Avihingsanon ◽  
Romanee Chaiwarith ◽  
Pacharee Kantipong ◽  
David Boettiger ◽  
...  
Keyword(s):  
Prediction Model ◽  
Predictive Value ◽  
Cd4 Count ◽  
High Rate ◽  
First Line ◽  
Data Set ◽  
Factors Associated ◽  
Hiv Rna ◽  
Hiv Exposure ◽  
Rna Levels

Abstract Background The use of abacavir (ABC) and rilpivirine (RPV) in the first-line regimen for naïve HIV-infected patients with pretreatment HIV RNA >100,000 copies/mL is not recommended due to a high rate of treatment failure. If a model could accurately predict pretreatment HIV RNA levels, it would be a useful tool for the selection ABC or RPV in the first-line regimen. Methods Thai HIV-infected adults enrolled in the TREAT Asia HIV Observational Database (TAHOD) and additional patients of Ramathibodi Hospital were eligible if they had an HIV RNA result at the time of antiretroviral therapy initiation. Factors associated with pretreatment HIV RNA <100,000 copies/mL were determined by logistic regression. Based on the results of the final model, a prediction model was created. Results A total of 1,223 patients were included in the analysis. Among those in the derivation data set, median [interquartile range (IQR)] age was 36.3 (30.5–42.9) years, median (IQR) CD4 count was 122 (39–216) cells/mm3, and pretreatment HIV RNA was 100,000 (32,449–229,777) copies/mL. Factors associated with pretreatment HIV RNA <100,000 copies/mL were anemia [odds ratio (OR) 2.05 vs. no anemia; 95% confidence interval (CI) 1.28–3.27], CD4 count >200 cells/mm3 (OR 3.00 vs. CD4 count <200 cells/mm3; 95% CI 2.08–4.33), and non-heterosexual HIV exposure (OR 1.61 vs. heterosexual HIV exposure; 95% CI 1.07–2.43). No AIDS-defining illness (11.5), no anemia (18.5), age <35 years (11), CD4 count >200 cells/mm3 (27), duration of HIV infection >1 year (9), and weight >50 years (11) were included in the clinical prediction tool scores. A score ≥45 yielded a sensitivity of 45.3%, specificity of 76.7%, positive predictive value of 68.1%, and negative predictive value of 56.1% among patients in the derivation. The area under the receiver-operator characteristic curve was 0.655 (95% CI 0.614- 0.696) and 0.600 (95% CI 0.533–0.667) in the derivation and validation patients, respectively. Conclusion Our final prediction model had poor sensitivity and specificity for predicting HIV RNA <100,000 copies/mL. Further study on a larger population with a greater diversity of data variables available is necessary to improve the model. Pretreatment HIV RNA remains necessary before ABC or RPV initiation for naïve Thai HIV-infected patients. Disclosures All authors: No reported disclosures.

scholarly journals PHV23: PATIENT ADHERENCE WITH MULTI-DRUG HIV THERAPY: VARIATIONS IN ADHERENCE AND CORRELATION WITH HIV RNA LEVELS

2000 ◽  
Vol 3 (2) ◽  
pp. 125
Author(s):  
K.C Farmer ◽  
C Rathbun ◽  
P Clay ◽  
J Stephens ◽  
T Bui ◽  
...  
Keyword(s):  
Patient Adherence ◽  
Hiv Therapy ◽  
Hiv Rna ◽  
Rna Levels
Sign in / Sign up

Export Citation Format

Share Document